Mono Efficacy of Capecitabine (MoniCa)
NCT00196820 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2011-10-06
Summary
Study done in patients with metastatic breast cancer in order to determine the efficacy of capecitabine
Conditions
Interventions
- DRUG
Sponsors & Collaborators
- collaborator INDUSTRY
-
GBG Forschungs GmbH
lead OTHER
Principal Investigators
-
Manfred Kaufmann, MD · Klinikum der J. W. Goethe Universität, Universitätsfrauenklinik
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-07-31
- Completion
- 2008-12-31
Countries
- Germany
Study Locations
More Related Trials
-
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer
NCT06156761 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00829166 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT04965064 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
NCT02597868 ·Status: UNKNOWN ·Phase: NA
-
Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00274768 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
NCT00721630 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
NCT05063136 ·Status: RECRUITING ·Phase: PHASE3
-
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
NCT00005649 ·Status: COMPLETED ·Phase: PHASE2
-
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
NCT02650752 ·Status: COMPLETED ·Phase: PHASE1
-
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
NCT00049660 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
NCT00967031 ·Status: COMPLETED ·Phase: PHASE2
-
Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
NCT00130533 ·Status: COMPLETED ·Phase: PHASE3
-
Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer
NCT01196455 ·Status: UNKNOWN ·Phase: PHASE2
-
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
NCT00684216 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
NCT00534417 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
NCT03204734 ·Status: UNKNOWN ·Phase: PHASE2
-
An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)
NCT00589901 ·Status: UNKNOWN ·Phase: PHASE2
-
CP-724,714 in Treating Patients With Metastatic Breast Cancer
NCT00055926 ·Status: COMPLETED ·Phase: PHASE1
-
Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer
NCT01924078 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
NCT00087620 ·Status: TERMINATED ·Phase: PHASE4
-
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
NCT01130259 ·Status: NO_LONGER_AVAILABLE
-
TBP Study With Capecitabine Plus Minus Trastuzumab
NCT00148876 ·Status: COMPLETED ·Phase: PHASE3
-
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
NCT00031876 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
NCT03286842 ·Status: COMPLETED ·Phase: PHASE3
-
Capecitabine in Low Risk Triple Negative Breast Cancer
NCT06787339 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2